Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.61 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.57 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SCD | O00767 | 1/20 | 0.51 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206986 | 0.90 | PTGS2 (0.73) | PTGS2DRD1SCDFADS1PTGS1 | |
| SCHEMBL7087905 | 0.85 | PTGS2 (0.46) | PTGS2GRIA4DRD1PTGS1 | |
| SCHEMBL7084454 | 0.83 | PTGS2 (0.59) | PTGS2DRD1PTGS1 | |
| SCHEMBL8485289 | 0.77 | PTGS2 (0.70) | PTGS2DRD1PTGS1 | |
| SCHEMBL10825673 | 0.76 | GRIA4 (0.54) | GRIA4 | |
| SCHEMBL215130 | 0.76 | PTGS2 (1.00) | PTGS2DRD1PTGS1 | |
| SCHEMBL14955951 | 0.76 | PTGS2 (0.52) | PTGS2GRIA4SCDFADS1PTGS1 | |
| SCHEMBL10436028 | 0.74 | MAOB (0.65) | GRIA4 | |
| SCHEMBL18559001 | 0.74 | TDP1 (0.52) | GRIA4 | |
| SCHEMBL6732658 | 0.74 | PTGS2 (0.70) | PTGS2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885GRIA4 2050/4885DRD1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.